Abstract
Models of tolerance are commonly derived on empirical grounds, because of lack of knowledge about the mechanism of tolerance or because of the difficulty of appropriately simplifying complex physiological processes. The present study was performed to evaluate the interchangeability of tolerance models used in the literature and to address some determinants for selection of an appropriate design and data analysis strategy.
Seven models were chosen (noncompetitive antagonist model, partial agonist model, reverse agonist model, direct moderator model, indirect moderator model, pool model and adaptive pool model) along with their corresponding parameter estimates, representing a wide range of empirical models.
The performance of the models on various data sets was evaluated. Data were simulated from each original model and were further analysed by the other models. The effect-time course of each and every data set could be described well by at least 2 different empirical tolerance models, but no model could describe all the data sets adequately. However, all models could adequately describe at least 2 different data sets. This indicates that, without additional knowledge or assumptions, it is unlikely that reliable mechanistic information can be deduced from the mere fact that 1 (or more) of these models can describe the data. Generally, data expressing only limited tolerance can be described by a wide variety of models, whereas few models will be appropriate for data characterised by extensive tolerance.
The models that gave an adequate description of a data set were selected for further study that investigated their predictive capacity based on the parameters previously determined. Predictions were made for 4 different administration schemes. The selected models gave similar predictions for the extended designs of 3 data sets for which the original study designs characterised tolerance well. For the other 4 data sets, the selected models gave disparate predictions, although the models described the original data set well. Thus, the predictive capability of a model was linked to the original study design, whereas the correlation between predictive performance and the type of model was weak or absent. Based on the results, factors of importance for the design and evaluation of studies of tolerance were identified and discussed.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Castañeda-Hernández G, Caille G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin Pharmacokinet 1994; 26: 135–43.
Bauer JA, Fung HL. Pharmacodynamic models of nitroglycerin-induced hemodynamic tolerance in experimental heart failure. Pharm Res 1994; 11: 816–23.
Movin-Osswald G, Hammarlund-Udenaes M. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther 1995; 274: 921–7.
Pratt JA. Psychotropic drug tolerance and dependence: common underlying mechanisms? In: Pratt JA, editor. The biological bases of drug tolerance and dependence. London: Academic Press, 1991: 1–28.
Way EL. Opioid tolerance and physical dependence and their relationship. In: Herz A, editor. Opioids II. Berlin: Springer-Verlag, 1993: 573–96.
Jaffe JH, Martin WR. Opioid analgesics and antagonists. In: Gilman AG, Rall TW, Nies AS, et al. editors. The pharmacological basis of therapeutics. New York: Pergamon, 1990: 533.
Collin E, Cesselin F. Neurobiological mechanisms of opioid tolerance and dependence. Clin Neuropharmacol 1991; 14: 465–88.
Johnson SM, Fleming WF, Mechanism of cellular adaptive sensitivity changes: application to opioid tolerance and dependence. Pharmacol Rev 1989; 41: 435–88.
Porchet HC, Benowitz NL, Sheiner LB. Pharmacodynamic model of tolerance: application to nicotine. J Pharmacol Exp Ther 1988; 244: 231–6.
Hammarlund MM, Odlind B, Paalzow LK. Acute tolerance to furosemide diuresis in humans: pharmacokinetic-pharmacodynamic modeling. J Pharmacol Exp Ther 1985; 233: 447–53.
Sheiner LB. Clinical pharmacology and the choice between theory and empiricism. Clin Pharmacol Ther 1989; 46: 605–15.
Shi J, Benowitz NL, Denaro CP, et al. Pharmacokinetic-pharmacodynamic modeling of caffeine: tolerance to pressor effects. Clin Pharmacol Ther 1993; 53: 6–14.
Ekblom M, Hammarlund-Udenaes M, Paalzow L. Tolerance development and rebound effects of morphine in relation to different administrations in rats. J Pharmacol Exp Ther 1993; 266: 244–52.
Gårdmark M, Ekblom M, Bouw R, et al. Quantification of effect delay and acute tolerance development to morphine in the rat. J Pharmacol Exp Ther 1993; 267: 1061–7.
Ouellet DM-C, Pollack GM. A pharmacokinetic-pharmacodynamic model of tolerance to morphine analgesia during infusion in rats. J Pharmacokinet Biopharm 1995; 23: 531–49.
Fattinger K, Verotta D, Benowitz NL. Pharmacodynamics of acute tolerance to multiple nicotinic effects in humans. J Pharmacol Exp Ther 1997; 281: 1238–46.
Lau CE, Heatherington AC. Pharmacokinetic-pharmacodynamic modeling of stimulatory and sedative effects of alprazolam: timing performance deficits. J Pharmacol Exp Ther 1997; 283: 1119–29.
Lau CE, Fang MA, Foster DM, et al. Pharmacokinetic-pharmacodynamic modeling of the psychomotor stimulant effect of cocaine after intravenous administration: timing performance deficits. J Pharmacol Exp Ther 1999; 288: 535–43.
Ekblad EBM, Licko V. A model eliciting transient responses. Am J Physiol 1984; 246: R114–21.
Holford NHG, Gabrielsson JL, Sheiner LB, et al. A physiological pharmacodynamic model for tolerance to cocaine effects on systolic blood pressure, heart-rate and euphoria in human volunteers: measurement and kinetics of in vivo drug effects. Noordwijk (The Netherlands): LACDR, 1990: 48.
Xu Z-X, Sun Y-N, DuBois DC, et al. Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm 1995; 23: 163–81.
Wakelkamp M, Alván G, Gabrielsson J, et al. Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther 1996; 60: 75–88.
Gårdmark M, Karlsson MO, Jonsson F, et al. Morphine-3-glucuronide has a minor effect on morphine antinociception: pharmacodynamic modeling. J Phar Sci 1998; 87 (7): 813–20.
Sharma A, Ebling WF, Jusko WJ. Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci 1998; 87: 1577–84.
Sun Y, McKay LI, DuBois DC, et al. Pharmacokinetic/pharmacodynamic models for corticosteroids receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a receptor/gene-mediated mechanism. J Pharmacol Exp Ther 1999; 288: 720–8.
Francheteau P, Steimer J-L, Merdjan H, et al. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharm 1993; 21: 489–514.
Veng-Pedersen P, Modi NB. A system approach to pharmacodynamics: input-effect control system analysis of central nervous system effect of alfentanil. J Pharm Sci 1993; 82: 266–75.
Mandema JW, Wada DR. Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J Pharmacol Exp Ther 1995; 275: 1185–94.
Fattinger KE, Verotta D, Porchet HC, et al. Modeling a bivariate control system: LH and testosterone response to the GnRH antagonist antide. Am J Physiol 1996; 271: E775–8.
Chow MJ, Ambre JJ, Ruo TI, et al. Kinetics of cocaine distribution, elimination, and chronotropic effects. Clin Pharmacol Ther 1985; 38: 318–24.
Kroboth PD, Smith RB, Erb RJ. Tolerance to alprazolam after intravenous bolus and continuous infusion: psychomotor and EEG effects. Clin Pharm Ther 1988; 43: 270–7.
Ambre JJ, Belknap SM, Nelson J, et al. Acute tolerance to cocaine in humans. Clin Pharmacol Ther 1988; 44: 1–8.
Lima JJ, Krukemyer JJ, Boudoulas H. Drug- or hormone-induced adaptation: model of adrenergic hypersensitivity. J Pharmacokinet Biopharm 1989; 17: 347–64.
Holford NHG. Parametric models of the time-course of drug action. In: van Boxtel CJ, Holford NHG, Danhof M, editors. The in vivo study of drug action. Amsterdam: Elsevier, 1992: 61–9.
Segre G, Turco GL, Vercellone G. Modelling blood glucose and insulin kinetics in normal, diabetic and obese subjects. Diabetes 1972; 22: 94–103.
Ceresa F, Ghemi F, Martini PF, et al. Control of blood glucose in normal and diabetic subjects. Diabetes 1968; 17: 570–8.
Gabrielsson J, Weiner D. Pharmacokinetic and pharmacodynamic data analysis. Stockholm: Swedish Pharmaceutical Press, 1994.
Movin-Osswald G, Hammarlund-Udenaes M. Remoxipride: pharmacokinetics and effect on plasma prolactin. Br J Clin Pharmacol 1991; 32: 355–60.
Beal SL, Sheiner LB. NONMEM Users’s Guides: NONMEM Project Group. San Francisco: University of California at San Francisco, 1992.
Jonsson EN, Karlsson MO. X-pose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51–64.
Mathsoft. S-PLUS Reference manual, version 3.4. Seattle: Mathsoft, 1997.
Paalzow LK, Edlund PO. Multiple receptor responses: a new concept to describe the relationship between pharmacological effects and pharmacokinetics of a drug: studies on Clonidine in the rat and cat. J Pharmacokinet Biopharm 1979; 7: 495–510.
Shafer SL, Varvel JR, Aziz N, et al. Pharmacokinetics of fentanyl administrated by computer-controlled infusion pump. Anesthesiology 1990; 73: 1091–102.
Francheteau P, Steimer J-L, Dubray C, et al. Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203–922. J Pharmacokinet Biopharm 1991; 19: 287–309.
Gårdmark M, Hammarlund-Udenaes M. Delayed antinociceptive effect following morphine-6-glucuronide administration in the rat: pharmacokinetic-pharmacodynamic modelling. Pain 1998 Feb; 74 (2–3): 287–96.
Packer M, Lee WH, Kessler PD, et al. Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N Engl J Med 1987; 317: 799–804.
Kleinbloesem CH, van Brummelen D, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41: 20–30.
Gårdmark M, Höglund AU, Hammarlund Udenaes M. Aspects on tail-flick, hot-plate and electrical stimulation tests for morphine antinociception. Pharmacol Toxicol 1998; 83: 252–8.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gårdmark, M., Brynne, L., Hammarlund-Udenaes, M. et al. Interchangeability and Predictive Performance of Empirical Tolerance Models. Clin Pharmacokinet 36, 145–167 (1999). https://doi.org/10.2165/00003088-199936020-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003088-199936020-00005